AlloCure Raises $14.5M

Salt Lake City-based AlloCure said Wednesday that the firm has raised $14.5M in a Series A financing round. The round came from SV Life Sciences, which led the round, along with Novo A/S. AlloCure is a biotechnology firm developing therapies for the treatment of acute kidney injury. The firm said the funding would go towards funding its acute kidney disease therapy through Phase II clinical trials, over the next three years. More information »